Substance Misuse

Dáil Éireann Debate, Thursday - 14 December 2017

Thursday, 14 December 2017

Questions (392, 393, 412, 413, 414, 417, 418, 419, 420, 421, 423, 425)

Billy Kelleher

Question:

392. Deputy Billy Kelleher asked the Minister for Health the number of HSE staff who have received training in 2017 on SAOR screening and brief intervention for problem alcohol and substance use. [53843/17]

Billy Kelleher

Question:

393. Deputy Billy Kelleher asked the Minister for Health the number of new patients that have received access to naxolone in 2017. [53844/17]

Billy Kelleher

Question:

412. Deputy Billy Kelleher asked the Minister for Health the number of adults who have been deemed appropriate for treatment for substance use in 2017; and the number who have received treatment within one calendar month, by LHO, in tabular form. [53863/17]

Billy Kelleher

Question:

413. Deputy Billy Kelleher asked the Minister for Health the number of children who have been deemed appropriate for treatment for substance use in 2017; and the number who have received treatment within one week, by LHO, in tabular form. [53864/17]

Billy Kelleher

Question:

414. Deputy Billy Kelleher asked the Minister for Health if he will report on the review of services in all CHOs in relation to the person-centred care planning processes of the drugs rehabilitation framework reassessment, key working and care planning. [53865/17]

Billy Kelleher

Question:

417. Deputy Billy Kelleher asked the Minister for Health if he will report on the HSE training programme for addiction staff, level 2 general practitioners and pharmacists in relation to buprenorphine naloxone and buprenorphine products. [53868/17]

Billy Kelleher

Question:

418. Deputy Billy Kelleher asked the Minister for Health the increase in addiction residential treatment beds and additional treatment episodes that has been provided in 2017. [53869/17]

Billy Kelleher

Question:

419. Deputy Billy Kelleher asked the Minister for Health if he will report on the development of integrated care pathways and referral pathways from the pharmacy needle exchange to other agencies. [53870/17]

Billy Kelleher

Question:

420. Deputy Billy Kelleher asked the Minister for Health the details of the expansion of other paraphernalia such as foil within the pharmacy needle exchange programme to allow persons the option of smoking rather than injecting. [53871/17]

Billy Kelleher

Question:

421. Deputy Billy Kelleher asked the Minister for Health the status of the guidelines and strategic statement on hidden harm. [53872/17]

Billy Kelleher

Question:

423. Deputy Billy Kelleher asked the Minister for Health the average waiting time from referral to assessment for opioid substitution treatment. [53874/17]

Billy Kelleher

Question:

425. Deputy Billy Kelleher asked the Minister for Health the average waiting time from opioid substitution assessment to exit from waiting list or treatment commenced. [53876/17]

Written answers

Minister of State at the Department of Health

I propose to take Questions Nos. 392, 393, 412 to 414, inclusive, 417 to 421, inclusive, 423 and 425 together.

As these are service matters, they have been referred to the Health Service Executive for attention and direct reply to the Deputy.